IQE plc was notified yesterday that on 9 October 2014, the following directors of the Company (the "Directors") exercised options over ordinary shares of 1p each in the Company (the "New Ordinary Shares"):
Name | Director | No. of options over Ordinary Shares | Exercise Price | New Ordinary Shares |
Dr. Drew Nelson | Chief Executive Officer | 300,000 | 10.166p | 300,000 |
Dr. Drew Nelson | Chief Executive Officer | 4,500,753 | nil cost | 4,500,753 |
Dr. Howard Williams | Chief Operations Officer | 1,870,535 | nil cost | 1,870,535 |
Phillip Rasmussen | Chief Finance Officer | 1,870,535 | nil cost | 1,870,535 |
Following this exercise of options, the Directors have the following beneficial interests in the Company's issued share capital ("ISC"):
Name | Director | No. of options over Ordinary Shares | Options over Ordinary Shares as a % of ISC | No. of Ordinary Shares | Ordinary Shares as a % of ISC |
Dr. Drew Nelson | Chief Executive Officer | 3,145,433 | 0.47% | 34,125,885 | 5.18% |
Dr. Howard Williams | Chief Operations Officer | 3,319,715 | 0.50% | 3,542,965 | 0.54% |
Phillip Rasmussen | Chief Finance Officer | 2,391,252 | 0.36% | 2,723,357 | 0.41% |
Application has been made to the London Stock Exchange for 8,541,823 New Ordinary Shares issued pursuant to the exercise of options to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective on 16 October 2014 and the New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares in issue. Following Admission, the Company's enlarged ISC will be 658,134,599 Ordinary Shares. All of these Ordinary Shares carry voting rights of one vote per Ordinary Share. There are no Ordinary Shares held in treasury and so the total number of voting rights in the Company is currently 658,134,599.
Contacts:
IQE plc +44 (0) 29 2083 9400
Drew Nelson
Phil Rasmussen
Chris Meadows
Canaccord Genuity + 44 (0) 20 7523 8000
Simon Bridges
Cameron Duncan